Mohammad Hosseininejad-Chafi - Biotechnology Research Center, Venom & Biotherapeutics Molecules Lab, Pasteur Institute of Iran, Tehran, Iran
Ehsan Alirahimi - Biotechnology Research Center, Venom & Biotherapeutics Molecules Lab, Pasteur Institute of Iran, Tehran, Iran
Behzad Ramezani - Biotechnology Research Center, Venom & Biotherapeutics Molecules Lab, Pasteur Institute of Iran, Tehran, Iran
Akbar Oghalaei - Biotechnology Research Center, Venom & Biotherapeutics Molecules Lab, Pasteur Institute of Iran, Tehran, Iran
Nazli Sotoudeh - Biotechnology Research Center, Venom & Biotherapeutics Molecules Lab, Pasteur Institute of Iran, Tehran, Iran
Hajarsadat Ghaderi - Biotechnology Research Center, Venom & Biotherapeutics Molecules Lab, Pasteur Institute of Iran, Tehran, Iran
Fatemeh Kazemi-Lomedasht - Biotechnology Research Center, Venom & Biotherapeutics Molecules Lab, Pasteur Institute of Iran, Tehran, Iran
Mahdi Habibi-Anbouhi - National Cell Bank, Pasteur Institute of Iran, Tehran, Iran
Reza Moazzami - Human Genetics Research Center, Baqiyatallah University of Medical Sciences, Tehran, Iran
Mahdi Behdani - Biotechnology Research Center, Venom & Biotherapeutics Molecules Lab, Pasteur Institute of Iran, Tehran, Iran

Objective(s): A variety of signaling molecules have been identified that play a role in angiogenesis, of prime importance, vascular endothelial growth factor (VEGF) and its resceptor (VEGFR), which is highly expressed in most human solid tumors. Targeting VEGF or/and VEGFR with immunotoxin may be a promising approach to directly affect cancer cells. Immunotoxins are for targeted treatment comprising two functional moieties, an antibody that binds to target cells along with toxin that kills molecules.  Materials and Methods: In this study, an immunotoxin comprising domain of diphtheria toxin subunit A (DT۳۸۶) genetically fused to mouse VEGF (mVEGF-DT) was developed. The second construct, which contains the DT۳۸۶ domain, was made to investigate the action of the DT۳۸۶ domain on tumor cells. Both gene constructs were cloned, expressed, and were further purified. The biological activity of mVEGF-DT and DT۳۸۶ proteins was assessed on the TC۱ cell line bearing mouse model. Proteins were injected intra-tumoral in mice, in separate groups. Results: Tumors in the mVEGF-DT group started to dwindle after six injections, but tumor size in both control groups (DT۳۸۶ and PBS), continued to grow. Conclusion: Successful targeting of solid tumor cells by mVEGF-DT immunotoxin demonstrates the therapeutic potential utility of these conjugates for tumor targeting.

Angiogenesis, Immunotherapy, Immunotoxin, Tumor, Vascular endothelial growth - factor (VEGF)